Markets:

Overview

News

Currencies

International

Treasuries

Pliant Therapeutics, Inc. - Common Stock (NQ:PLRX)

1.239 +0.029 (+2.38%)

Streaming Delayed Price Updated: 9:40 AM EST, Dec 8, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Pliant Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >

Pliant Therapeutics Receives Orphan Designation from the European Medicines Agency for Bexotegrast (PLN-74809) for the Treatment of Idiopathic Pulmonary Fibrosis

December 15, 2022

From Pliant Therapeutics, Inc.

Via GlobeNewswire

12 Health Care Stocks Moving In Friday's Pre-Market Session ↗

December 02, 2022

Via Benzinga

Pliant Therapeutics to Participate in Upcoming Investor Conferences

November 15, 2022

From Pliant Therapeutics, Inc.

Via GlobeNewswire

Where Pliant Therapeutics Stands With Analysts ↗

September 01, 2022

Analysts have provided the following ratings for Pliant Therapeutics (NASDAQ:PLRX) within the last quarter:

Via Benzinga

Expert Ratings for Pliant Therapeutics ↗

August 09, 2022

Within the last quarter, Pliant Therapeutics (NASDAQ:PLRX) has observed the following analyst ratings:

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For December 14, 2022 ↗

December 14, 2022

Via Benzinga

Pliant Therapeutics Provides Corporate Update and Reports Third Quarter 2022 Financial Results

November 08, 2022

From Pliant Therapeutics, Inc.

Via GlobeNewswire

3 Soaring Biotech Stocks That Could Climb Much Higher ↗

October 20, 2022

These drugmakers have bucked the overall market's downward trend this year and expectations are still high.

Via The Motley Fool

Pliant Therapeutics to Participate in the RBC Biotech Expert Insights Series: Pulmonary/Lung Disease Mini-Symposium

October 05, 2022

From Pliant Therapeutics, Inc.

Via GlobeNewswire

Why Adamis Pharmaceuticals Is Trading Lower By Around 44%, Here Are 46 Stocks Moving In Wednesday's Mid-Day Session ↗

September 21, 2022

Gainers

Via Benzinga

Why Stabilis Solutions Shares Jumped Over 71%; Here Are 70 Biggest Movers From Yesterday ↗

September 22, 2022

Gainers

Via Benzinga

Pliant Therapeutics Inc. (NASDAQ: PLRX) Climbs to New 52-Week High

September 14, 2022

Via Investor Brand Network

Recap Of Thursday's Biotech Catalysts - End Of the Day Summary ↗

September 01, 2022

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For September 1, 2022 ↗

September 01, 2022

Upgrades

Via Benzinga

7 Cheap Biotech Stocks to Buy Now ↗

August 03, 2022

These cheap biotech stocks to buy offer investors a way to get ready for the inevitable comeback in the biopharmaceutical sector.

Via InvestorPlace

Pliant Therapeutics Secures FDA Fast Track Status For Liver Disease Drug ↗

July 21, 2022

Pliant Therapeutics (NASDAQ: PLRX) received Fast Track designation for its lead asset PLN-74809 from the U.S. Food and Drug Administration (FDA) for the potential treatment of primary sclerosing...

Via Benzinga

4 Analysts Have This to Say About Pliant Therapeutics ↗

July 20, 2022

Over the past 3 months, 4 analysts have published their opinion on Pliant Therapeutics (NASDAQ:PLRX) stock. These analysts are typically employed by large Wall Street banks and tasked with...

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For July 20, 2022 ↗

July 20, 2022

Upgrades

Via Benzinga

The Daily Biotech Pulse: AstraZeneca's COVID-19 Vaccine As Effective As mRNA Shots, Humanigen's Lenzilumab Disappoints In COVID-19 Study, Positive Preclinical Data From Hoth's Alzheimer's Program ↗

July 13, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

Boeing, PriceSmart And 80 Biggest Movers From Yesterday ↗

July 13, 2022

Gainers Sharps Compliance Corp. (NASDAQ: SMED) shares jumped 196.1% to close at $8.44 on Tuesday after the company it will be acquired by an affiliate of Aurora Capital Partners for $8.75 per share.

Via Benzinga

Why Is Canoo Surging By 80%? 52 Stocks Moving In Tuesday's Mid-Day Session ↗

July 12, 2022

Gainers

Via Benzinga

Short Volatility Alert: Pliant Therapeutics, Inc. ↗

July 12, 2022

On Monday, shares of Pliant Therapeutics, Inc. (NASDAQ: PLRX) experienced volatile short activity. After the activity, the stock price went up +159.01% to $23.00. The overall sentiment for PLRX has...

Via Benzinga

The Daily Biotech Pulse: GSK To Supply 50M Flu Vaccine Doses To US, FDA Lifts Hold On Greenwich's Cancer Immunotherapy Trial, Connect Biopharma Sees CBP-201 Topline Data Sooner ↗

July 12, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

What's Going On With Pliant Therapeutics Stock? ↗

July 12, 2022

Pliant Therapeutics Inc (NASDAQ: PLRX) shares are trading lower Tuesday after the company announced a proposed $150 million offering.

Via Benzinga

Alibaba, Zoom Video And 76 Biggest Movers From Yesterday ↗

July 12, 2022

Gainers Kaspien Holdings Inc. (NASDAQ: KSPN) shares climbed 161.9% to close at $6.81 on Monday on heavy volume amid mention of the stock on social media.

Via Benzinga

After-Hours Alert: Why Pliant Therapeutics Stock Is Moving ↗

July 11, 2022

Pliant Therapeutics Inc (NASDAQ: PLRX) shares are volatile in Monday's after-hours session after the company announced a proposed $150 million offering.

Via Benzinga

Dow Dips Around 90 Points; La Jolla Pharmaceutical Shares Surge ↗

July 11, 2022

U.S. stocks traded lower toward the end of trading as investors digested the recent jobs report for the month of June.

Via Benzinga

12 Health Care Stocks Moving In Monday's Intraday Session ↗

July 11, 2022

Via Benzinga

Stocks Lower Midday as Tech Slumps ↗

July 11, 2022

Stocks are lower midday, with the Dow Jones Industrial Average and Nasdaq Composite both down triple digits, as investors prepare for this week's inflation data and the start of earnings season.

Via Talk Markets

Pliant Therapeutics Stock Just Doubled And Hit A 10-Month High — Here's Why ↗

July 11, 2022

The company's IPF treatment is proving itself where others didn't.

Via Investor's Business Daily

< Previous 1 2 3 4 5 6 7 8 9 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.